bpc-157 not approved for human use fda statement Committee Votes to Ease Restrictions on Six Peptides An FDA advisory panel voted

Responsible BPC-157 reporting should make uncertainty more visible, not use scientific vocabulary to hide it

It impairs recovery from training

doi: 10.1016/j.tranon.2015.06.004 111 ZhaoXLiuJGeSChenCLiSWuXet al

In 2023, the FDA finalized its reclassification of several peptide compounds including BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, and others removing them from the list of bulk drug substances permitted for compounding under Section 503A and 503B of the Food Drug and Cosmetic Act

The increased collagen availability allows for more efficient tissue regeneration during rehabilitation from injuries or intense training periods